Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA(TM) (bevacizumab gamma) for the Treatment of Wet AMD

Stock Information for Acasti Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Acasti Pharma Inc.

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Outlook Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference
JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA(TM) (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.